149 related articles for article (PubMed ID: 36837525)
1. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
[No Abstract] [Full Text] [Related]
2. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Martino EA; Mauro FR; Reda G; Laurenti L; Visentin A; Frustaci A; Vigna E; Pepe S; Catania G; Loseto G; Murru R; Chiarenza A; Sportoletti P; Del Principe MI; Laureana R; Coscia M; Galimberti S; Ferretti E; Zucchetto A; Bomben R; Polesel J; Tedeschi A; Rossi D; Trentin L; Neri A; Morabito F; Gattei V; Gentile M
Hematol Oncol; 2024 Jan; 42(1):e3249. PubMed ID: 38287529
[TBL] [Abstract][Full Text] [Related]
4. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Tedeschi A; Frustaci AM; Mauro FR; Chiarenza A; Coscia M; Ciolli S; Reda G; Laurenti L; Varettoni M; Murru R; Baratè C; Sportoletti P; Greco A; Borella C; Rossi V; Deodato M; Biagi A; Zamprogna G; Pelle AC; Lapietra G; Vitale C; Morelli F; Cassin R; Fresa A; Cavalloni C; Postorino M; Ielo C; Cairoli R; Di Raimondo F; Montillo M; Del Poeta G
Blood Adv; 2021 Dec; 5(24):5490-5500. PubMed ID: 34525181
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
Gordon MJ; Jones JE; George B; Peterson C; Burger JA; Jain N; Keating M; Wierda WG; Durand JB; Ferrajoli A
Cancer; 2023 Jul; 129(14):2192-2200. PubMed ID: 37016930
[TBL] [Abstract][Full Text] [Related]
6. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
O'Brien S; Furman RR; Coutre S; Flinn IW; Burger JA; Blum K; Sharman J; Wierda W; Jones J; Zhao W; Heerema NA; Johnson AJ; Luan Y; James DF; Chu AD; Byrd JC
Blood; 2018 Apr; 131(17):1910-1919. PubMed ID: 29437592
[TBL] [Abstract][Full Text] [Related]
7. Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.
Huntington SF; de Nigris E; Puckett JT; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong EM; Leng S; Yang X; Doshi JA
Cancer Med; 2024 Jan; 13(2):e6953. PubMed ID: 38348963
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
Huntington SF; de Nigris E; Puckett J; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong E; Leng S; Yang X; Doshi JA
Leuk Lymphoma; 2023 Dec; 64(14):2286-2295. PubMed ID: 37870435
[TBL] [Abstract][Full Text] [Related]
9. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK.
Hillmen P; Xie J; Yong ASM; Waweru C; Sorof TA; Goyal RK; Davis KL
EJHaem; 2021 May; 2(2):219-227. PubMed ID: 35845284
[TBL] [Abstract][Full Text] [Related]
11. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
Parikh SA; Achenbach SJ; Call TG; Rabe KG; Ding W; Leis JF; Kenderian SS; Chanan-Khan AA; Koehler AB; Schwager SM; Muchtar E; Fonder AL; McCullough KB; Nedved AN; Smith MD; Slager SL; Kay NE; Finnes HD; Shanafelt TD
Cancer Med; 2020 May; 9(10):3390-3399. PubMed ID: 32187452
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Byrd JC; Hillmen P; O'Brien S; Barrientos JC; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Barr PM; Furman RR; Kipps TJ; Thornton P; Moreno C; Montillo M; Pagel JM; Burger JA; Woyach JA; Dai S; Vezan R; James DF; Brown JR
Blood; 2019 May; 133(19):2031-2042. PubMed ID: 30842083
[TBL] [Abstract][Full Text] [Related]
13. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.
Walker C; Horowitz A; Nooruddin Z; Frei CR
J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.
Williams AM; Baran AM; Casulo C; Reagan P; Friedberg JW; Helber M; Moore J; Baloga E; Zent CS; Barr PM
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):41-47. PubMed ID: 30409718
[TBL] [Abstract][Full Text] [Related]
15. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Mauro FR; Scalzulli PR; Scarfò L; Minoia C; Murru R; Sportoletti P; Frigeri F; Albano F; Di Renzo N; Sanna A; Laurenti L; Massaia M; Cassin R; Coscia M; Patti C; Pennese E; Tafuri A; Chiarenza A; Galieni P; Perbellini O; Selleri C; Califano C; Ferrara F; Cuneo A; Murineddu M; Palumbo G; Scortechini I; Tedeschi A; Trentin L; Varettoni M; Pane F; Liberati AM; Merli F; Morello L; Musuraca G; Tani M; Ibatici A; Regazzoni G; Di Candia M; Palma M; Arienti D; Molica S
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539561
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review.
Sardar M; Malik SU; Khan A; Idrees M; Ahmad Q; Sohail C; Naseer R; Amin S; McBride A; Abuzar M; Safdar A; Chakraborty R; Lee P; Sharon D; Anwer F
J Hematol; 2019 Mar; 8(1):1-10. PubMed ID: 32300434
[TBL] [Abstract][Full Text] [Related]
17. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
Roeker LE; DerSarkissian M; Ryan K; Chen Y; Duh MS; Wahlstrom SK; Hakre S; Yu L; Guo H; Mato AR
Blood Adv; 2023 Aug; 7(16):4291-4301. PubMed ID: 37163361
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Burger JA; Barr PM; Robak T; Owen C; Ghia P; Tedeschi A; Bairey O; Hillmen P; Coutre SE; Devereux S; Grosicki S; McCarthy H; Simpson D; Offner F; Moreno C; Dai S; Lal I; Dean JP; Kipps TJ
Leukemia; 2020 Mar; 34(3):787-798. PubMed ID: 31628428
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Shanafelt TD; Wang XV; Hanson CA; Paietta EM; O'Brien S; Barrientos J; Jelinek DF; Braggio E; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Little RF; Erba H; Stone RM; Litzow M; Tallman M; Kay NE
Blood; 2022 Jul; 140(2):112-120. PubMed ID: 35427411
[TBL] [Abstract][Full Text] [Related]
20. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry.
Ghosh N; Sharman JP; Gutierrez M; Khan W; Qureshi ZP; Raz A; Girardi V; Krigsfeld GS; Barrientos JC
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38845276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
